Merck-话题@MedSci

#Merck#

8篇内容 | 1062人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1661836, encodeId=70de166183646, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, objectType=article, longId=208490, objectId=f6302084901e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6302084901e, replyNumber=0, likeNumber=73, createdTime=2022-02-11, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6302084901e, moduleTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6302084901e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661835, encodeId=f0ae166183532, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, objectType=article, longId=202471, objectId=94642024e127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94642024e127, replyNumber=0, likeNumber=74, createdTime=2021-05-01, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94642024e127, moduleTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94642024e127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661834, encodeId=f041166183411, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=默克（Merck）首席财务官强调：我们不仅有Keytruda, objectType=article, longId=182340, objectId=e72b182340f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e72b182340f8, replyNumber=0, likeNumber=82, createdTime=2020-05-28, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e72b182340f8, moduleTitle=默克（Merck）首席财务官强调：我们不仅有Keytruda, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e72b182340f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661831, encodeId=4ceb16618311f, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症, objectType=article, longId=163429, objectId=01811634295d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01811634295d, replyNumber=0, likeNumber=70, createdTime=2019-09-20, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01811634295d, moduleTitle=FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01811634295d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661833, encodeId=bd141661833ae, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, objectType=article, longId=177568, objectId=24091e7568e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24091e7568e4, replyNumber=0, likeNumber=79, createdTime=2020-04-28, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24091e7568e4, moduleTitle=Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24091e7568e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661832, encodeId=ae6016618325b, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎, objectType=article, longId=167634, objectId=b63116e634f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b63116e634f3, replyNumber=0, likeNumber=78, createdTime=2019-09-07, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b63116e634f3, moduleTitle=Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b63116e634f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661830, encodeId=6bf5166183077, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=FDA接受Merck制药关于克拉屈滨治疗多发性硬化症的申请, objectType=article, longId=145542, objectId=252f1455429f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=252f1455429f, replyNumber=0, likeNumber=96, createdTime=2018-10-18, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=252f1455429f, moduleTitle=FDA接受Merck制药关于克拉屈滨治疗多发性硬化症的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=252f1455429f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1661829, encodeId=d5a5166182941, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, objectTitle=Merck被曝用印度儿童测试癌症疫苗, objectType=article, longId=45580, objectId=d3fd45580ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3fd45580ea, replyNumber=0, likeNumber=99, createdTime=2015-03-27, rootId=0, userName=1249859em46(暂无昵称), userId=845e25340050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3fd45580ea, moduleTitle=Merck被曝用印度儿童测试癌症疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3fd45580ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Merck

2020-05-29

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望

2022-02-11

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体

2021-05-01

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

默克（Merck）首席财务官强调：我们不仅有Keytruda

2020-05-28

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症

2019-09-20

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

Oncologie宣布与Merck进行临床试验合作，评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌

2020-04-28

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎

2019-09-07

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

FDA接受Merck制药关于克拉屈滨治疗多发性硬化症的申请

2018-10-18

1249859em46(暂无昵称) (审核中...)

前往app查看评论内容

#Merck#

Merck被曝用印度儿童测试癌症疫苗

2015-03-27

科室
- - 订阅+
  - 更多科室
工具
服务